SCHEMBL21296943

SCHEMBL21296943

COc1ccc(Sc2[nH]nnc2C(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
HAO1 Q9UJM8 2/20 0.43
ALPL P05186 2/20 0.43
CA9 Q16790 1/20 0.43
PRKAG1 P54619 2/20 0.42
PRKAA1 Q13131 2/20 0.42
PRKAB1 Q9Y478 2/20 0.42
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP12 P39900 1/20 0.39
FFAR1 O14842 1/20 0.39
CSNK2A2 P19784 1/20 0.38
CSNK2A1 P68400 1/20 0.38
PRKAB2 O43741 1/20 0.38
PRKAA2 P54646 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21312777 0.96 PRKAG1 (0.48) CA1CA2HAO1ALPLCA9
SCHEMBL22772688 0.85 ALPL (0.46) HAO1ALPLPRKAG1PRKAA1PRKAB1
SCHEMBL21296965 0.84 SMN1; SMN2 (0.41) HAO1ALPLCA9ALDH1A1KDM4E
SCHEMBL21312821 0.84 HAO1 (0.37) HAO1ALDH1A1MEN1KMT2AKDM4E
SCHEMBL21296967 0.83 NPC1 (0.48) ALDH1A1HTTKDM4ENPC1RAB9A
SCHEMBL21312819 0.82 RHEB (0.46) DHFRNPC1RAB9A
SCHEMBL21312820 0.82 KMT2A (0.38) HAO1ALDH1A1MEN1KMT2AKDM4E
SCHEMBL21312823 0.82 ALDH1A1 (0.37) HAO1ALDH1A1MEN1HTTKMT2A
SCHEMBL23319917 0.81 RHEB (0.40) HAO1ALPLMEN1KMT2A
SCHEMBL21296958 0.81 HAO1 (0.54) HAO1ALPLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX CA1 764/4885CA2 560/4885HAO1 14/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX CA1 764/4885CA2 560/4885HAO1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.